395 related articles for article (PubMed ID: 22660976)
1. The role of PARP1 in the DNA damage response and its application in tumor therapy.
Wang Z; Wang F; Tang T; Guo C
Front Med; 2012 Jun; 6(2):156-64. PubMed ID: 22660976
[TBL] [Abstract][Full Text] [Related]
2. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
Li M; Yu X
Oncogene; 2015 Jun; 34(26):3349-56. PubMed ID: 25220415
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
4. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
8. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
9. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
10. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
Wiśnik E; Ryksa M; Koter-Michalak M
Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
12. Mitotic functions of poly(ADP-ribose) polymerases.
Slade D
Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
[TBL] [Abstract][Full Text] [Related]
13. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
[TBL] [Abstract][Full Text] [Related]
14. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
15. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Redon CE; Nakamura AJ; Zhang YW; Ji JJ; Bonner WM; Kinders RJ; Parchment RE; Doroshow JH; Pommier Y
Clin Cancer Res; 2010 Sep; 16(18):4532-42. PubMed ID: 20823146
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage.
Matkarimov BT; Zharkov DO; Saparbaev MK
Mutagenesis; 2020 Feb; 35(1):107-118. PubMed ID: 31782485
[TBL] [Abstract][Full Text] [Related]
17. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Mégnin-Chanet F; Bollet MA; Hall J
Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
[TBL] [Abstract][Full Text] [Related]
18. PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses.
Song J; Keppler BD; Wise RR; Bent AF
PLoS Genet; 2015 May; 11(5):e1005200. PubMed ID: 25950582
[TBL] [Abstract][Full Text] [Related]
19. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
20. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]